Polymorphisms Contribution to the Determination of Significant Risk of Specific Toxicities in Multiple Myeloma
Authors: Almáši M., Ševčíková S., Šváchová H., Sáblíková B., Májková P., Hájek R.
Authors - sphere of activity: 1 Laboratory of Experimental Hematology and Cell Immunotherapy, Department of Clinical Hematology, University Hospital Brno, Czech Republic
2 Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
3 Department of Internal Medicine – Hematooncology, University Hospital Brno, Czech Republic
Article: Klin Onkol 2011; 24(Supplementum 1): 39-42
Number of articles displayed: 152x
The introduction of new drugs improved clinical response of patients with diagnosed multiple myeloma (MM); however, MM is still an incurable disease that leads to frequent relapses. Individual genetic variability can significantly affect therapeutic response, sensitivity and toxicity. Analysis of single nucleotide polymorphisms (SNPs) to study genetic changes is the genomic method that can obtain information for improving the effectiveness of treatment with minimum undesirable toxicity followed by individual treatments. The aim of this paper is to explain the possibility of detection and evaluation of polymorphisms associated with toxicity of treatment in patients with MM.
single nucleotide polymorphisms (SNPs) – genotyping – real-time PCR – allelic discrimination – toxicity – multiple myeloma
This work was supported by research grants of The Ministry of Education, Youth and Sports: LC06027, MSM0021622434; research projects of IGA of The Ministry of Health: NS10207, NS10406, NT11154 and grant of GACR GAP304/10/1395.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
The full wording of this article is available only to registered users. Plese register and you can read this article immediately.
If you are a subscriber, log in and enter the subscriber code from your magazine cover.
If you are not a subscriber, log in for unlimited access to older editions.
Tento článek si můžete přečíst pokud si aktivujete Premium účet.
- Cancer as a Metabolic Disease and Diabetes as a Cancer Risk? | views: 51
- The Role of Platelets in Tumour Growth | views: 25
- p63 – an Important Player in Epidermal and Tumour Development | views: 16
- PThe Regulation of p53 Synthesis | views: 13
- Detection of Cancer Stem Cell Markers in Sarcomas | views: 12
- Protein Quality Control and Cancerogenesis | views: 11
- RECAMO – ...through Cancer Research towards Applied Molecular Oncology; Where, Why and How | views: 8
- NKT-like Cells are Expanded in Solid Tumour Patients | views: 7
- The Many Roles of Molecular Chaperones and Co-chaperones in Tumour Biology | views: 7
- Circulating Levels of B-cell Activating Factor in Paediatric Patients with Malignancy With or without Cancer-Related Cachexia | views: 4